Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Dr. Carl V. Crawford is an Assistant Professor of Medicine and Attending Physician at the New York Presbyterian-Weill Cornell Medical Center in Division of Gastroenterology and Hepatology.   Dr. Crawford completed his undergraduate studies in 1996 at Georgetown University with a degree in Biology.  He received his medical degree in 2001 from the Yale University School of Medicine after completing a Howard Hughes Medical Institute Research Fellowship in 1998 there as well.  He subsequently completed his internship and residency training in Internal Medicine in 2004 at the New York Presbyterian Hospital – Weill Cornell Campus. He spent the following year studying the mechanisms by which dietary components prevent solid tumors under a National Institutes of Health Research Training Grant.  He then completed his fellowship in Gastroenterology and Hepatology in 2008 at the Weill Cornell Campus.  He is also the recipient of the Louis and Rudin Foundation Grant for the Study of Enteric Pathogens,   Dr. Crawford has a wide variety of interests including gastrointestinal tumors, bleeding and infections. One of his academic interests is the evaluation and management of enteric infections including Clostridium difficile. He is currently involved in fecal microbiota transfers (FMT) or fecal transplant for refractory cases of CDI.  In addition, he is involved in the evaluation and treatment of small bowel diseases using Single Balloon Enteroscopy. He is a member of the American College of Gastroenterology, the American and New York Societies of Gastrointestinal Endoscopy, and the American Gastroenterological Association.    

Highlights

  1. 1
    Endoscopy international open · 2021
    RERussell Evan RosenblattCVCarl V. Crawford
    PMID: 34079880PMCID: PMC8159624DOISenior author
  2. 2
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    GGGaurav GhoshJZJonathan ZippinCVCarl V. Crawford
    PMID: 33130008DOISenior author2 citations

Publications

51 publications

Funding

2 grants

Active

2 grants
  • Co-I
    Changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for synucleinopathies
    National Institute of Neurological Disorders and Stroke · 2024–2029
    R01NS136423-01A1
  • Co-I
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2022–2027
    UL1TR002384-06

Clinical research

9 studies

Active

5 studies
  • PI
    FMT and Other Gut Microbial Therapies National Registry: Acute Severe and Fulminant C. Difficile Infection
    American Gastroenterological Association · OPEN TO ACCRUAL (as of 2026)
  • PI
    FMT and Other Gut Microbial Therapies National Registry
    American Gastroenterological Association · OPEN TO ACCRUAL (as of 2025)
  • PI
    A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
    PHASE3 · Vedanta Biosciences, Inc. · OPEN TO ACCRUAL (as of 2025)
    Clostridium Difficile; Clostridium Difficile Infections; Clostridium Difficile Infection Recurrence; Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; CDI; C. Diff Infection; Recurrent Clostridium Difficile Infection; C.Difficile Diarrhea; Diarrhea Infectious
    NCT06237452
  • PI
    A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
    PHASE2; PHASE3 · Lumen Bioscience, Inc. · OPEN TO ACCRUAL (as of 2024)
    Clostridioides Difficile Infection
    NCT05330182
  • PI
    Conservative Management vs. Endoscopy for Gastrointestinal Bleeding in Patients with Hematologic Malignancies
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
Completed & closed trials (4)
  • PI
    REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
    Ferring Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2026)
    Recurrence of Clostridium Difficile Infection
    NCT05835219
  • PI
    Spatially Resolved Metagenomics to Explore Tumor-Microbiome Interactions in Human Colorectal Cancer
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
  • PI
    A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides Difficile Infection (CDI)
    PHASE3 · Finch Research and Development LLC · IRB STUDY CLOSURE (as of 2023)
    Recurrent C. Difficile Infection
    NCT05153499
  • PI
    A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
    PHASE1 · Artugen Therapeutics USA, Inc. · IRB STUDY CLOSURE (as of 2022)
    Clostridium Difficile Infection Recurrence
    NCT04891965

Mentoring

1 menteeAll publications with mentees →

External relationships

Advisory/Scientific Board Member

Ferring Pharmaceuticals, Inc. · Nestlé Health Science